SGLT2阻害薬は，脱水が影響していると考えられる重篤な副作用の報告があり，体重減少がどの部分でもたらされているか知ることは重要と思われる。

　タニタマルチ周波数体組成計（MC190）を用い、SGLT2阻害薬服用後の体組成の変化を調べた。その結果，内服1ヵ月～6ヵ月後において体脂肪率40％以上の患者では体重の減少は主に体脂肪の減少によってもたらされているのに対し，体脂肪率40％未満の患者では、体脂肪も減少するが，筋肉と水分の減少が大きいことがわかった。よって，SGLT2阻害薬は，体脂肪率40％以上の症例が良い適応と考えられた。

    Because serious adverse effects possibly associated with dehydration have been reported with sodium-glucose cotransporter 2 (SGLT2) inhibitors, it is important to characterize the changes in body composition responsible for weight loss induced by the agents.

   We assessed changes in body composition after the administration of SGLT2 inhibitors using a Tanita multi-frequency body composition analyzer (MC-190). After 1-6 months of administration, weight loss in patients with a body fat percentage of ≥40% was predominantly due to a decrease in their fat mass, while that in those with <40% body fat was largely attributed to a decrease in their muscle and water mass, although fat loss did occur. The results suggest that SGLT2 inhibitors are suitable for use in patients with a body fat percentage of ≥40%.